HBIO HARVARD BIOSCIENCE INC
Laboratory Analytical Instruments · Nasdaq · SEC CIK 1123494 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY2.3%
TTM net income YoY78.1%
TTM EPS YoY173.1%
Revenue 3-yr CAGR-7.4%
Net income 3-yr CAGR—
Margins
Gross margin57.4%
Operating margin-1.8%
Net margin-13.2%
FCF margin-3.5%
EBITDA margin0.3%
Returns
ROE-123.1%
ROA-15.4%
ROIC (approx.)-3.2%
Asset turnover1.17x
Leverage & solvency
Liabilities / assets93.2%
Debt / equity7.28x
Current ratio1.76x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.06x
Accruals ratio-14.5%
Payout ratio—
Capex / revenue2.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $86.55M | $94.14M | $112.25M | $113.33M | $118.90M |
| Cost of revenue | $36.64M | $39.37M | $46.18M | $52.52M | $51.25M |
| Gross profit | $49.91M | $54.77M | $66.07M | $60.82M | $67.65M |
| R&D expense | $8.82M | $10.41M | $11.76M | $12.33M | $10.80M |
| SG&A expense | $17.74M | $21.49M | $22.76M | $24.49M | $24.30M |
| Operating income | -$48.58M | -$6.21M | $1.89M | -$6.93M | $2.07M |
| Interest expense | $3.60M | $3.20M | — | — | — |
| Pretax income | -$57.39M | -$11.66M | -$2.56M | -$9.18M | -$140,000 |
| Income tax | -$686,000 | $740,000 | $859,000 | $337,000 | $148,000 |
| Net income | -$56.70M | -$12.40M | -$3.42M | -$9.52M | -$288,000 |
| EBITDA | -$46.84M | -$4.48M | $3.37M | -$5.48M | $3.85M |
| EPS (basic) | -1.28 | -0.28 | -0.08 | -0.23 | -0.01 |
| EPS (diluted) | -1.28 | -0.28 | -0.08 | -0.23 | -0.01 |
| Weighted avg. shares (diluted) | 44.39M | 43.54M | 42.42M | 41.41M | 40.34M |
| Balance sheet | |||||
| Cash & equivalents | $8.61M | $4.11M | $4.28M | $4.51M | $7.82M |
| Receivables | $16.04M | $14.87M | $16.10M | $16.70M | $21.83M |
| Inventory | $20.80M | $23.25M | $24.72M | $26.44M | $27.59M |
| Current assets | $48.23M | $45.12M | $49.04M | $51.12M | $61.58M |
| PP&E, net | $4.79M | $5.11M | $3.98M | $3.37M | $3.42M |
| Goodwill | $9.56M | $56.32M | $57.06M | $56.26M | $57.69M |
| Intangibles | $7.64M | $11.13M | $16.04M | $21.01M | $27.39M |
| Total assets | $80.07M | $126.64M | $137.37M | $145.36M | $162.34M |
| Current liabilities | $21.96M | $54.96M | $26.54M | $23.25M | $25.32M |
| Short-term debt | $0 | $36.96M | $6.14M | $4.09M | $3.52M |
| Long-term debt | $35.87M | $0 | $36.96M | $43.01M | $45.09M |
| Total debt | $35.87M | $36.96M | $43.09M | $47.10M | $48.61M |
| Total liabilities | $66.34M | $63.30M | $64.29M | $73.14M | $78.94M |
| Shareholders' equity | $13.73M | $63.34M | $73.07M | $72.22M | $83.40M |
| Net debt | $27.26M | $32.85M | $38.81M | $42.60M | $40.79M |
| Shares outstanding | 4.47M | 44.07M | 43.39M | 42.08M | 41.14M |
| Cash flow statement | |||||
| Operating cash flow | $6.73M | $1.44M | $14.03M | $1.15M | $1.26M |
| Capital expenditure | $1.26M | $2.64M | $1.79M | $1.59M | $1.20M |
| Free cash flow | $5.47M | -$1.20M | $12.24M | -$438,000 | $67,000 |
| Investing cash flow | -$1.86M | -$1.34M | -$1.80M | -$1.59M | -$1.34M |
| Financing cash flow | -$1.29M | -$131,000 | -$12.13M | -$2.84M | -$252,000 |
| Depreciation & amortization | $1.74M | $1.73M | $1.47M | $1.45M | $1.78M |
| Stock-based compensation | $1.85M | $4.34M | $5.00M | $4.41M | $4.17M |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.